Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-1033 in Metastatic Breast Cancer
NCT00051051Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2002
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of canertinib in breast cancer (3 arms), sponsored by Pfizer. Primary endpoint: Antitumor Activity. Started Dec 2002; status: completed.
02
Drugs
canertinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00051051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00051051.